ISPOR EU 2025
ISPOR EU 2025
New Alzheimer's Disease White Paper
New Alzheimer's Disease White Paper
RWE for Regulatory Decision-Making
RWE for Regulatory Decision-Making
Landmark and IQVIA collaboration
White paper on best practices for RWE for regulatory filings

Services

Designing and generating RWE for regulatory submissions including externally controlled trials (ECTs), natural history, benchmarking studies, and epidemiological support on orphan drug applications, pediatric study plans, diversity plans, and (s)BLAs/(s)NDAs.

Designing and conducting a range of observational studies including burden of disease, comparative effectiveness & safety, and external control arms. We provide end-to-end execution including study design, protocol and analysis plan writing, analysis, study report, and publications.

Conducting targeted or systematic literature reviews to inform comparative effectiveness and confounder selection, incidence and prevalence across indications, treatment patterns, and outcomes.

Identifying suitable data sources for novel research questions and conducting data assessments & feasibility by indication to determine fitness of data. We have extensive experience with medical claims databases, electronic health record data, genomic, and registry data.

Designing and conducting healthcare resource utilization, budget impact models, and cost effectiveness studies and data to support HTA/payor needs.

Writing services include protocol and statistical analysis plan writing, and abstract, poster and manuscript development. Experience with medical writing in the context of real-world evidence.

Success Stories


Screenshot 2024-11-01 201701
Screenshot 2024-11-01 211945

Looking for support in generating RWE?

 
 
 
 
 

We offer flexible and custom solutions to meet your needs. Contact us to initiate a dialogue.

Call nowEmail us